Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-Label 40-week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
Conditions
Interventions
Atogepant
Locations
113
United States
Synexus Clinical Research US, Inc.
Chandler, Arizona, United States
Alea Research
Phoenix, Arizona, United States
Central Phoenix Medical Clinic
Phoenix, Arizona, United States
Orange Grove Family Practice
Tucson, Arizona, United States
Principals Research Group
Hot Springs, Arkansas, United States
Arkansas Clinical Research
Little Rock, Arkansas, United States
Start Date
May 6, 2019
Primary Completion Date
March 31, 2021
Completion Date
March 31, 2021
Last Updated
May 12, 2022
NCT05734625
NCT06248671
NCT07103694
NCT06938178
NCT03432286
NCT05207865
Lead Sponsor
Allergan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions